Painchek (ASX:PCK) 3-Year Book Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PCK Painchek Ltd ASX:PCK
41 GF Score
Price A$0.11
GF Value A$0.42
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Painchek 3-Year Book Growth Rate?

Painchek ASX:PCK +4.76% 41 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates ASX:PCK with a GF Score™ of 41/100 and a GF Value™ of A$0.42 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 581 Healthcare Providers & Services companies, Painchek ranks worse than 172116.87% on this metric.

Painchek's Book Value per Share for the quarter that ended in Jun. 2026 was A$0.00.

During the past 12 months, Painchek's average Book Value per Share Growth Rate was -7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Painchek was 23.70% per year. The lowest was -55.40% per year. And the median was -44.40% per year.


Painchek  (ASX:PCK) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Painchek 3-Year Book Growth Rate Related Terms


ASX:PCK vs VEEV, BTSG, TEM: 3-Year Book Growth Rate Comparison

For the Health Information Services subindustry, Painchek's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Painchek 3-Year Book Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Painchek's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Painchek's 3-Year Book Growth Rate falls into.


ASX:PCK
41GF Score
Painchek Ltd ASX:PCK
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Painchek 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Painchek (ASX:PCK) has a 3-Year Book Growth Rate of 0.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Painchek and its competitors. According to the industry distribution chart, Painchek ranks #999999 out of 581 companies in the Healthcare Providers & Services industry.
Is Painchek's 3-Year Book Growth Rate too high?
Painchek's current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, Painchek ranks #999999 out of 581 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Painchek has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's 3-Year Book Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #999999 out of 581 companies for 3-Year Book Growth Rate. This places Painchek in the lower half of its industry. The industry median 3-Year Book Growth Rate is 5.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Healthcare Providers & Services company?
The median 3-Year Book Growth Rate among Healthcare Providers & Services companies is 5.40, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Painchek and its competitors. For the Healthcare Providers & Services industry, the median 3-Year Book Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.42, compared to a current price of A$0.11 — trading 73.8% below its estimated fair value. The current 3-Year Book Growth Rate is 0.00%. Painchek's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Painchek (ASX:PCK), the current 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Painchek (ASX:PCK) Overvalued in 2026?

Based on GuruFocus' analysis, Painchek stock appears to be undervalued. The current stock price of A$0.11 is trading 73.8% below its estimated GF Value™ of A$0.42. GuruFocus considers Painchek to be Possible Value Trap.

Key valuation signals for ASX:PCK:

  • 3-Year Book Growth Rate: 0.00%
  • GF Value™: A$0.42 vs. price of A$0.11 (73.8% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
41GF Score

Get the complete analysis for ASX:PCK

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.42
GF Value